Bina Desai

This paper introduces a spatial-statistical framework to quantify stroma-tumor cell interactions from histology, showing geometric limits and applying it to identify proliferation bias in cancer.

This study shows that stromal niches protect lung cancers from ALK inhibitors through multiple mechanisms, and targeting these mechanisms together is more effective than targeting them individually.

This paper identifies CYP3A4 hyperactivation as a tumor-extrinsic resistance mechanism in NSCLC, showing it reduces drug exposure and leads to resistance, and proposes dosing optimization and CYP3A4 inhibition as solutions.

This study identifies that CAFs confer ALK inhibitor resistance in EML4-ALK-driven lung cancer through both MET and integrin signaling pathways, and shows that targeting both pathways improves treatment efficacy.

This paper develops and validates a treatment strategy called evolutionary antifragile therapy, which uses treatment fluctuations to limit tumor resistance evolution.

This study shows that combining trastuzumab deruxtecan with sotorasib improves responses in KRASG12C-mutant NSCLC and overcomes resistance, but HER2 expression levels influence treatment effectiveness.

This study combines radiotherapy and NK cell immunotherapy to exploit an evolutionary double-bind strategy in prostate cancer, showing that RT-resistant cells become more vulnerable to NK cell killing.